AU2020263295B2 — Mini softgel naproxen composition
Assigned to RP Scherer Technologies LLC · Expires 2025-01-23 · 1y expired
What this patent protects
Disclosed herein are mini softgel capsules comprising a reaction product of naproxen free acid and potassium hydroxide in a molar ratio of potassium hydroxide to naproxen free acid of less than about 1. Also disclosed herein are methods for treating patients in need thereof with …
USPTO Abstract
Disclosed herein are mini softgel capsules comprising a reaction product of naproxen free acid and potassium hydroxide in a molar ratio of potassium hydroxide to naproxen free acid of less than about 1. Also disclosed herein are methods for treating patients in need thereof with the mini softgel capsules as well as methods for stabilizing mini softgel capsules that include a fill composition that has a high concentration of active agent.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.